EANO Meeting - Saturday, September 17, 2022
Note that the programme is subject to change and will be continuously updated. Speaker and presentation details will be published in due course.
All times below refer to Central European Summer Time (CEST).
08:00-09:00 hrs
Chairs: tba
WU01.1 Molecularly informed trials – experience from N2M2
Wolfgang Wick, Germany
WU01.2 "Leveraging external data in the analysis of clinical trials in neuro-oncology"
Patrick Wen, United States
WU01.3 How much translational program is needed for early clinical trials
Susan Chang, United States
Chairs: tba
WU02.1 Physical exercise and fatigue in patients with glioma
Shawn Hervey-Jumper, United States
WU02.2 Experience with supervised activities in rehabilitation
Dorothee Wiewrodt, Germany
WU02.3 Type of Exercise to Optimize Quality of Life in Patients with High-Grade Glioma
Dominik Cordier, Switzerland
Chairs: tba
WU03.1 Relapsed medulloblastoma
Paul Northcott, United States
WU03.2 Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma
Raelene Endersby, Australia
WU03.3 Exploring MB subgroup complexity
Michael Taylor, Canada
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Chairs: tba
JS04.1 Reprogamming therapies
Mariella Filbin, United States
JS04.2 Clinical Trials - a transatlantic perspective
Sabine Müller, United States
JS04.3 Immunotherapies
Hideho Okada, United States
JS04.4 Origin and models
tba
Chairs: tba
JS05.1 Joined forces in surgical neuro-oncology
Matthias Simon, Germany
JS05.2 Electrophsyological monitoring of Brain:tumor crosstalk and implications
Shawn Hervey-Jumper, United States
JS05.3 Should we preserve functions at the cost of survival?
Ole Solheim, Norway
JS05.4 Intraoperative strategies in glioma resection; complication avoidance and optimising EOR
Tamara Ius, Italy
JS05.5 Navigated transcranial magnetic stimulation in brain surgery planning
Giuseppe Lucente, Spain
Chairs: tba
OS06.1 Quality of life in clinical trials
Martin Taphoorn, Netherlands
OS06.2 Remote consultations (telemedicine) in neuro-oncology
Ekokobe Fonkem, United States
OS06.3 Caregiver outcomes: constructs and measures
Caroline Hertler, Switzerland
10:45-11:15 hrs | COFFEE BREAK
11:15-12:45 hrs
Chairs: tba
OS09.1 Survivorship in paediatric brain tumours
Emma Nicklin, United Kingdom
OS09.2 Late effects of brain tumour treatment
Louise Murray, United Kingdom
OS09.3 From Surviving to Thriving: A Model for a Holistic Neuro-Oncology Survivorship Program
Naomi Hoffer, United States
12:45-14:15 hrs | LUNCH BREAK
13:00-14:00 hrs
Chairs: tba
Two groups of 13 participants will discuss the topic with two mentors each. The setup allows for open, in depth discussions and every participant is encouraged to interact with the mentors. After 30 minutes the groups will switched, so each participant gets a chance to speak to all mentors.
WS03.1 Project planning (where to start and where to end)
Manuel Valiente, Spain
WS03.2 Project planning (where to start and where to end)
Gelareh Zadeh, Canada
WS03.3 Cover letter, methodology, revision process
Simone Niclou, Luxembourg
WS03.4 tba
Ulrike Harjes, United States
14:15-15:45 hrs
Chairs: tba
OS10.1 Cell states and fate transitions in glioblastoma
Gaetano Gargiulo, Germany
OS10.2 Proteogenomic and metabolomic characterization of human glioblastoma
tba
OS10.3 Interactions between cancer cells and immune cells
Itay Tirosh, Israel
Chairs: tba
OS11.1 Immunotherapy of leptomeningeal disease
Ghazaleh Tabatabai, Germany
OS11.2 Leptomeningeal Metastases
Priya Kumthekar, United States
OS11.3 EANO-ESMO classification of leptomengial disease: clinical implications
Emilie Le Rhun, Switzerland
Chairs: tba
OS12.1 iWOT-trial: What can we learn?
Martin van den Bent, Netherlands
OS12.2 What to target next in LGG?
Wolfgang Wick, Germany
OS12.3 What are appropriate outcome measures in LGG trials?
Linda Dirven, Netherlands
OS12.4 Future trial designs
Matthias Preusser, Austria
15:45-16:00 hrs | BREAK
16:00-17:00 hrs
Chairs: tba
JS06.1 Progress report from EURACAN
Ahmed Idbaih, France
JS06.2 Building a registry for rare glioneural tumors: an EORTC project
Michael Weller, Switzerland
JS06.3 BRAF V600E mt gliomas: a treatment opportunity
Martin van den Bent, Netherlands
Chairs: tba
JS07.1 Innovative PET tracers in neurooncology
Antoine Verger, France
JS07.2 New PET imaging methods
Ian Law, Denmark
JS07.3 Metabolic PET imaging
Norbert Galldiks, Germany
